Journal
SCIENTIFIC REPORTS
Volume 12, Issue 1, Pages -Publisher
NATURE PORTFOLIO
DOI: 10.1038/s41598-022-26821-8
Keywords
-
Categories
Funding
- Deutsche Forschungsgemeinschaft (DFG
- German Research Foundation) [452622720, TR240 374031971]
- DFG [192904750, CRC 992, FOR 2674-2]
- Projekt DEAL
Ask authors/readers for more resources
Treatment of myelodysplastic syndromes with decitabine is crucial, and early platelet response can predict overall survival. However, the effect of decitabine on megakaryocytes and bone marrow needs further investigation.
Treatment of myelodysplastic syndromes includes the administration of the hypomethylating agent decitabine. An early platelet response in decitabine-treated myelodysplastic syndrome patients is a predictor of overall survival. The effect of decitabine on megakaryocytes and the bone marrow, however, is understudied. We show that an early platelet increment was not detectable in healthy mice during decitabine treatment. Analyses of bone marrow sections revealed vessels with dilated lumina, decreased cellularity, but increased number of red blood cells and the presence of (pro)platelet-like particles. Taken together, decitabine treatment of healthy mice does not induce an early platelet increment, but affects the bone marrow.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available